Phaseline

Companies › Agios Pharmaceuticals

Agios Pharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 15 registered trials: 7 Phase 3, 5 Phase 2, 3 Phase 1; Hematology, Metabolic and endocrine, Other; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Mitapivat
Pyruvate kinase isozymes R/L activator
PKLRPhase 3Non-Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Alpha-Thalassemia; Pediatric Pyruvate Kinase Deficiency; Sickle Cell Disease …Dec 2028
Tebapivat (AG-946)–Phase 2Sickle Cell Disease; Myelodysplastic SyndromesMay 2027
AG-181
Phenylalanine hydroxylase (PAH) activator
PAHPhase 1PhenylketonuriaJan 2028
AG-236–Phase 1Healthy Participants–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07075640AG-236Phase 1Healthy ParticipantsOtherFeb 2026
NCT06924970Tebapivat (AG-946)Phase 2Sickle Cell DiseaseHematologyMay 2027
NCT07241234AG-181Phase 1PhenylketonuriaMetabolic and endocrineJan 2028
NCT04610866MitapivatPhase 1Sickle Cell DiseaseHematologyFeb 2028
NCT04770753MitapivatPhase 3Non-Transfusion-dependent Alpha-ThalassemiaHematologyDec 2028
NCT07517133MitapivatPhase 3Non-Transfusion-dependent Alpha-ThalassemiaHematologyMar 2029
NCT05490446Tebapivat (AG-946)Phase 2Myelodysplastic SyndromesHematologyMar 2029
NCT04770779MitapivatPhase 3Transfusion-dependent Alpha-ThalassemiaHematologyJun 2029
NCT07506863MitapivatPhase 3Transfusion-dependent Alpha-ThalassemiaHematologyJun 2029
NCT05144256MitapivatPhase 3Pediatric Pyruvate Kinase DeficiencyHematologyJun 2029
NCT07656415MitapivatPhase 3Sickle Cell DiseaseHematologyAug 2029
NCT07055243MitapivatPhase 2AnemiaHematologyOct 2029
NCT05175105MitapivatPhase 3Pediatric Pyruvate Kinase DeficiencyHematologyJan 2030
NCT05031780MitapivatPhase 2Sickle Cell DiseaseHematologyFeb 2030
NCT03692052MitapivatPhase 2ThalassemiaHematologySep 2030

From the company's SEC filings

Cash and short-term investments of $907m on 2026-09-30; operating cash outflow about $316m a year; runway about 34 months at that burn, to Aug 2029; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PKLR (1) PAH (1)

Companies with the same targets

BioMarin Pharmaceutical Forma Therapeutics ScinnoHub Pharmaceutical Novo Nordisk PTC Therapeutics Chongqing Peg-Bio Biopharm NGGT NGGT (Suzhou) Biotechnology

Companies built like this

ScinnoHub Pharmaceutical Forma Therapeutics X4 Pharmaceuticals Nanjing Chia-tai Tianqing Pharmaceutical OPKO Health

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.